AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer

…, S Caenepeel, J Stevens, PJ Beltran, J Canon… - Clinical Cancer …, 2021 - AACR
Purpose: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high
relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor …

[PDF][PDF] Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition

…, CB Yohn, JS Joyal, D Marquess, PJ Beltran… - Cell metabolism, 2021 - cell.com
Attenuating pathological angiogenesis in diseases characterized by neovascularization
such as diabetic retinopathy has transformed standards of care. Yet little is known about the …

[HTML][HTML] Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

…, P Li, DB Allison, H Salimi-Moosavi, PJ Beltran… - Nature …, 2018 - nature.com
Diminished growth factor signaling improves longevity in laboratory models, while a
reduction in the somatotropic axis is favorably linked to human aging and longevity. Given the …

AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

PJ Beltran, P Mitchell, YA Chung, E Cajulis, J Lu… - Molecular cancer …, 2009 - AACR
Pancreatic carcinoma is a leading cause of cancer deaths, and recent clinical trials of a
number of oncology therapeutics have not substantially improved clinical outcomes. We have …

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

…, AM Boden, R Ponce, C Beers, PJ Beltran - Clinical Cancer …, 2017 - AACR
Purpose: Talimogene laherparepvec, a new oncolytic immunotherapy, has been recently
approved for the treatment of melanoma. Using a murine version of the virus, we characterized …

Discovery of 1H-Pyrazol-3(2H)-ones as Potent and Selective Inhibitors of Protein Kinase R-like Endoplasmic Reticulum Kinase (PERK)

…, H Beckmann, SF Bellon, PJ Beltran… - Journal of medicinal …, 2015 - ACS Publications
The structure-based design and optimization of a novel series of selective PERK inhibitors
are described resulting in the identification of 44 as a potent, highly selective, and orally …

[HTML][HTML] Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers

…, UP Dahal, T Wu, S Wannberg, PJ Beltran, J Canon… - Nature Cancer, 2024 - nature.com
Chromosomal instability (CIN) is a hallmark of cancer, caused by persistent errors in chromosome
segregation during mitosis. Aggressive cancers like high-grade serous ovarian cancer …

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

PJ Beltran, YA Chung, G Moody, P Mitchell… - … of Pharmacology and …, 2011 - ASPET
Ewing's and osteogenic sarcoma are two of the leading causes of cancer deaths in children
and adolescents. Recent data suggest that sarcomas may depend on the insulin-like growth …

Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth

J Carnahan, PJ Beltran, C Babij, Q Le, MJ Rose… - Molecular cancer …, 2010 - AACR
Raf inhibitors are under clinical investigation, specifically in patients with tumor types
harboring frequent activating mutations in B-Raf. Here, we show that cell lines and tumors …

Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results

…, R Juneau, M Buscarlet, S Chorfi, P Patel, PJ Beltran… - Nature Medicine, 2024 - nature.com
Compromised vascular endothelial barrier function is a salient feature of diabetic complications
such as sight-threatening diabetic macular edema (DME). Current standards of care for …